Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry

Henrik Christian Leffers; Mikkel Østergaard; Bente Glintborg; Niels Steen Krogh; Heidi Foged Henriksen; Ulrik Tarp; Tove Lorenzen; Annette Hansen; Michael Sejer Hansen; Martin Skov Jacobsen; Lene Dreyer; Merete Lund Hetland; All Departments of Rheumatology in Denmark; Lene Dreyer

doi:10.1136/ard.2010.140129

Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry

Henrik Christian Leffers, Mikkel Østergaard, Bente Glintborg, Niels Steen Krogh, Heidi Foged Henriksen, Ulrik Tarp, Tove Lorenzen, Annette Hansen, Michael Sejer Hansen, Martin Skov Jacobsen, Lene Dreyer, Merete Lund Hetland, All Departments of Rheumatology in Denmark, Lene Dreyer

103 Citationer (Scopus)

Abstract

Objectives: To describe drug survival, disease activity and clinical response in patients with rheumatoid arthritis (RA) treated with abatacept or tocilizumab in routine care, based on prospectively registered observational data from the nationwide Danish DANBIO registry. Methods: 150 Patients with RA treated with abatacept and 178 treated with tocilizumab were identified. Drug survival was investigated. Response data were available in 104 and 97 patients, respectively. Changes in 28-joint Disease Activity Score (DAS28) based on C-reactive protein (CRP) and European League Against Rheumatism (EULAR) response after 24 and 48 weeks were investigated. No direct comparison of drugs was made. Results: Median (IQR) disease duration was 8.5 (3-14)/9 (3-12) years (abatacept/tocilizumab). 95%/93% of patients had previously received one or more tumour necrosis factor inhibitor (TNFi). After 48 weeks, 54%/64% of patients (abatacept/tocilizumab) maintained treatment. Among patients with available response data, DAS28 was 5.3 (4.7-6.1), 3.4 (2.7-4.9) and 3.3 (2.5-4.3) at baseline, weeks 24 and 48, respectively, in the abatacept group and 5.4 (4.7-6.2), 2.9 (2.3-4.0) and 2.5 (1.9-4.5) in the tocilizumab group. At weeks 24 and 48, the remission rates for abatacept/tocilizumab were 19%/39% and 26%/58%, respectively. EULAR good-or-moderate response rates were 70%/88% and 77%/84%, respectively. The decline in DAS28 variables over time appeared similar between drugs, except for CRP, which seemed to decline more rapidly among tocilizumabtreated patients. Conclusions: In patients with RA (≥90% TNFi failures), a good-or-moderate EULAR response was achieved in ≥70% of patients treated with abatacept or tocilizumab for 24 weeks in routine care. Apparent declines in DAS28 variables over time were similar between drugs, except for the more rapid CRP decline among tocilizumab-treated patients, directly caused by interleukin 6 inhibition.

Originalsprog	Engelsk
Tidsskrift	Annals of the Rheumatic Diseases
Vol/bind	70
Udgave nummer	7
Sider (fra-til)	1216-22
Antal sider	7
ISSN	0003-4967
DOI	https://doi.org/10.1136/ard.2010.140129
Status	Udgivet - jul. 2011

Adgang til dokumentet

10.1136/ard.2010.140129

Citationsformater

Leffers, H. C., Østergaard, M., Glintborg, B., Krogh, N. S., Henriksen, H. F., Tarp, U., Lorenzen, T., Hansen, A., Hansen, M. S., Jacobsen, M. S., Dreyer, L., Hetland, M. L., All Departments of Rheumatology in Denmark, & Dreyer, L. (2011). Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Annals of the Rheumatic Diseases, 70(7), 1216-22. https://doi.org/10.1136/ard.2010.140129

Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. / Leffers, Henrik Christian; Østergaard, Mikkel ; Glintborg, Bente et al.
I: Annals of the Rheumatic Diseases, Bind 70, Nr. 7, 07.2011, s. 1216-22.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Leffers, HC, Østergaard, M , Glintborg, B, Krogh, NS, Henriksen, HF, Tarp, U, Lorenzen, T, Hansen, A, Hansen, MS, Jacobsen, MS, Dreyer, L, Hetland, ML, All Departments of Rheumatology in Denmark & Dreyer, L 2011, 'Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry', Annals of the Rheumatic Diseases, bind 70, nr. 7, s. 1216-22. https://doi.org/10.1136/ard.2010.140129

@article{541019c4b2604327994a5f05da076c25,

title = "Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry",

abstract = "Objectives: To describe drug survival, disease activity and clinical response in patients with rheumatoid arthritis (RA) treated with abatacept or tocilizumab in routine care, based on prospectively registered observational data from the nationwide Danish DANBIO registry. Methods: 150 Patients with RA treated with abatacept and 178 treated with tocilizumab were identified. Drug survival was investigated. Response data were available in 104 and 97 patients, respectively. Changes in 28-joint Disease Activity Score (DAS28) based on C-reactive protein (CRP) and European League Against Rheumatism (EULAR) response after 24 and 48 weeks were investigated. No direct comparison of drugs was made. Results: Median (IQR) disease duration was 8.5 (3-14)/9 (3-12) years (abatacept/tocilizumab). 95%/93% of patients had previously received one or more tumour necrosis factor inhibitor (TNFi). After 48 weeks, 54%/64% of patients (abatacept/tocilizumab) maintained treatment. Among patients with available response data, DAS28 was 5.3 (4.7-6.1), 3.4 (2.7-4.9) and 3.3 (2.5-4.3) at baseline, weeks 24 and 48, respectively, in the abatacept group and 5.4 (4.7-6.2), 2.9 (2.3-4.0) and 2.5 (1.9-4.5) in the tocilizumab group. At weeks 24 and 48, the remission rates for abatacept/tocilizumab were 19%/39% and 26%/58%, respectively. EULAR good-or-moderate response rates were 70%/88% and 77%/84%, respectively. The decline in DAS28 variables over time appeared similar between drugs, except for CRP, which seemed to decline more rapidly among tocilizumabtreated patients. Conclusions: In patients with RA (≥90% TNFi failures), a good-or-moderate EULAR response was achieved in ≥70% of patients treated with abatacept or tocilizumab for 24 weeks in routine care. Apparent declines in DAS28 variables over time were similar between drugs, except for the more rapid CRP decline among tocilizumab-treated patients, directly caused by interleukin 6 inhibition.",

author = "Leffers, {Henrik Christian} and Mikkel {\O}stergaard and Bente Glintborg and Krogh, {Niels Steen} and Henriksen, {Heidi Foged} and Ulrik Tarp and Tove Lorenzen and Annette Hansen and Hansen, {Michael Sejer} and Jacobsen, {Martin Skov} and Lene Dreyer and Hetland, {Merete Lund} and Mikkel {\O}stergaard and Lene Dreyer",

year = "2011",

month = jul,

doi = "10.1136/ard.2010.140129",

language = "English",

volume = "70",

pages = "1216--22",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "B M J Group",

number = "7",

}

TY - JOUR

T1 - Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry

AU - Leffers, Henrik Christian

AU - Østergaard, Mikkel

AU - Glintborg, Bente

AU - Krogh, Niels Steen

AU - Henriksen, Heidi Foged

AU - Tarp, Ulrik

AU - Lorenzen, Tove

AU - Hansen, Annette

AU - Hansen, Michael Sejer

AU - Jacobsen, Martin Skov

AU - Dreyer, Lene

AU - Hetland, Merete Lund

AU - All Departments of Rheumatology in Denmark

AU - Dreyer, Lene

PY - 2011/7

Y1 - 2011/7

N2 - Objectives: To describe drug survival, disease activity and clinical response in patients with rheumatoid arthritis (RA) treated with abatacept or tocilizumab in routine care, based on prospectively registered observational data from the nationwide Danish DANBIO registry. Methods: 150 Patients with RA treated with abatacept and 178 treated with tocilizumab were identified. Drug survival was investigated. Response data were available in 104 and 97 patients, respectively. Changes in 28-joint Disease Activity Score (DAS28) based on C-reactive protein (CRP) and European League Against Rheumatism (EULAR) response after 24 and 48 weeks were investigated. No direct comparison of drugs was made. Results: Median (IQR) disease duration was 8.5 (3-14)/9 (3-12) years (abatacept/tocilizumab). 95%/93% of patients had previously received one or more tumour necrosis factor inhibitor (TNFi). After 48 weeks, 54%/64% of patients (abatacept/tocilizumab) maintained treatment. Among patients with available response data, DAS28 was 5.3 (4.7-6.1), 3.4 (2.7-4.9) and 3.3 (2.5-4.3) at baseline, weeks 24 and 48, respectively, in the abatacept group and 5.4 (4.7-6.2), 2.9 (2.3-4.0) and 2.5 (1.9-4.5) in the tocilizumab group. At weeks 24 and 48, the remission rates for abatacept/tocilizumab were 19%/39% and 26%/58%, respectively. EULAR good-or-moderate response rates were 70%/88% and 77%/84%, respectively. The decline in DAS28 variables over time appeared similar between drugs, except for CRP, which seemed to decline more rapidly among tocilizumabtreated patients. Conclusions: In patients with RA (≥90% TNFi failures), a good-or-moderate EULAR response was achieved in ≥70% of patients treated with abatacept or tocilizumab for 24 weeks in routine care. Apparent declines in DAS28 variables over time were similar between drugs, except for the more rapid CRP decline among tocilizumab-treated patients, directly caused by interleukin 6 inhibition.

AB - Objectives: To describe drug survival, disease activity and clinical response in patients with rheumatoid arthritis (RA) treated with abatacept or tocilizumab in routine care, based on prospectively registered observational data from the nationwide Danish DANBIO registry. Methods: 150 Patients with RA treated with abatacept and 178 treated with tocilizumab were identified. Drug survival was investigated. Response data were available in 104 and 97 patients, respectively. Changes in 28-joint Disease Activity Score (DAS28) based on C-reactive protein (CRP) and European League Against Rheumatism (EULAR) response after 24 and 48 weeks were investigated. No direct comparison of drugs was made. Results: Median (IQR) disease duration was 8.5 (3-14)/9 (3-12) years (abatacept/tocilizumab). 95%/93% of patients had previously received one or more tumour necrosis factor inhibitor (TNFi). After 48 weeks, 54%/64% of patients (abatacept/tocilizumab) maintained treatment. Among patients with available response data, DAS28 was 5.3 (4.7-6.1), 3.4 (2.7-4.9) and 3.3 (2.5-4.3) at baseline, weeks 24 and 48, respectively, in the abatacept group and 5.4 (4.7-6.2), 2.9 (2.3-4.0) and 2.5 (1.9-4.5) in the tocilizumab group. At weeks 24 and 48, the remission rates for abatacept/tocilizumab were 19%/39% and 26%/58%, respectively. EULAR good-or-moderate response rates were 70%/88% and 77%/84%, respectively. The decline in DAS28 variables over time appeared similar between drugs, except for CRP, which seemed to decline more rapidly among tocilizumabtreated patients. Conclusions: In patients with RA (≥90% TNFi failures), a good-or-moderate EULAR response was achieved in ≥70% of patients treated with abatacept or tocilizumab for 24 weeks in routine care. Apparent declines in DAS28 variables over time were similar between drugs, except for the more rapid CRP decline among tocilizumab-treated patients, directly caused by interleukin 6 inhibition.

U2 - 10.1136/ard.2010.140129

DO - 10.1136/ard.2010.140129

M3 - Journal article

SN - 0003-4967

VL - 70

SP - 1216

EP - 1222

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 7

ER -

Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater